Funding for this research was provided by:
Robert Koch-Institut
Article History
Received: 1 November 2021
Accepted: 9 February 2022
First Online: 4 March 2022
Declarations
:
: <i>EMIS-2017</i> received a favourable ethical opinion from the Observational Research Ethics Committee at the London School of Hygiene and Tropical Medicine (review reference 14,421 /RR/8805) on 31 July 2017.The <i>PrApp-Survey</i> was approved by the ethics commission of the Berlin Chamber of Physicians (Ref: Eth-14/18). All participants had to provide informed consent before starting the survey.The authors confirm that all methods were carried out in accordance with relevant guidelines and regulations.
: Not applicable.
: U.K. owns ‘Exchange-traded fund’ (ETF) shares, which may include stocks of pharmaceutical companies that produce or develop PrEP. U.M., D.S. and S.B.S. declare that they have no competing interests.